In this study, and among over 10,000 participants, canakinumab (the human monoclonal antibody targeted at the IL-1ß) was shown to reduce the risk of the recurrence of myocardial infarction (MI), stroke, or death from cardiovascular causes by 15% in patients with CCS or after an MI [30]. Here, IL1B is linked to myocardial infarction.